Microfluidic Tumor Model for Drug Screening

CellASIC Corporation reports the application of microfluidic cell culture technology to create an in vitro tumor model for improved drug screening. This method, published in the journal Biotechnology Progress, creates an array of micro-bioreactors that mimic the mass transport properties of solid tumors. The array is formatted to a standard 96-well layout, making it compatible with existing screening instrumentation.

"This paper represents a key milestone in CellASIC's mission to develop the next generation of cell screening platforms," said Dr. Philip Lee, Director of Research at CellASIC. "We are now at a point where we can create precise arrays of complex microfluidic cell culture units in a user-friendly format. The next step is to scale the platform for implementation in high throughput automated assays."

This research was funded by the National Cancer Institute (NCI) Innovative Molecular Analysis Technologies (IMAT) Program and the National Science Foundation (NSF) Small Business Innovation Research (SBIR) Program.

About the Company

CellASIC Corporation specializes in developing microfluidic tools for live cell analysis. The core of the company’s technology is to engineer precise microscale environments to enable the next generation of biomedical research. This approach gives scientists an unprecedented level of control over experiential conditions leading to a more accurate understanding of how biological networks affect human health.

See related article at DrugResearcher.com

Request reprints of Biotechnology Progress manuscript

For more information, contact info@cellasic.com